Mental health studies with practical context.

A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor

Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013

Researchers studied ALKS 3831, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.

Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85.

Researchers compared ALKS 9072, Low and ALKS 9072, High, tracking side effects to assess long-term safety in people with schizophrenia.

This study evaluated the safety of Esketamine Nasal Spray for people with depression.

A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081

Researchers are studying Pomaglumetad methionil, tracking side effects to assess long-term safety in people with schizophrenia.

An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate CONCERTA (Methylphenidate HCL) Extended-release Tablets at Doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder

A Long-Term Study of JNS007ER in Patients With Schizophrenia

A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia